Publication | Closed Access

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Hematological MalignancyLymphoid NeoplasiaMedicine5-Year UpdatePathologyCancer TreatmentOncologyRadiation OncologyCancer ResearchStage IiiBrentuximab Vedotin